Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23, 14:00–17:30
AI for Science Reshaping Innovative Drug R&D Session
Stay tuned
Meeting Planner
Weijie Sun:Founder & CEO, DP Technology
14:00-14:10 Opening speech
14:10-14:30 AI for Science Infrastructure Development
Weijie Sun:Founder & CEO, DP Technology
14:30-14:50 AI & Robotics Empower Drug Discovery: Road to Autonomous Scientific Research
Jian Ma:Co-Founder & CEO,Xtalpi
14:50-15:10 From Technological Breakthroughs to Clinical Validation: The Second Half of AI-Driven Drug Development
Feng Ren:Co-CEO & CSO,Insilico Medicine
15:10-15:30 A New Paradigm in Drug Discovery: The Closed-Loop Leap with World Models and AI Scientists
Jeff He:Co-Founder & CEO,TandemAI
15:30-15:50 Tea Break
15:50-16:10 Applications of Artificial Intelligence in Peptide Drug Discovery
Frank Zhang:Co-Founder & CEO,Syneron Bio
16:10-16:30 AI-Driven New Drug R&D: The Intelligent Revolution in Drug Delivery
Chris Lai:Co-Founder, Chairman & CEO, METiS TechBio
16:30-16:50 AI Scientists Empower the Discovery and Validation of Novel Original Targets
Shuangjia Zheng:Researcher, Lingang Laboratory; Associate Professor, Shanghai Jiao Tong University
16:50-17:30 Roundtable: The Ultimate Competitiveness of AI Drug R&D — Differentiated Innovation or Original Source Innovation?
Weijie Sun:Founder & CEO, DP Technology
Jian Ma:Co-Founder & CEO,Xtalpi
Feng Ren:Co-CEO & CSO, Insilico Medicine
Jeff He:Co-Founder & CEO,TandemAI
Frank Zhang:Co-Founder & CEO,Syneron Bio
Chris Lai:Co-Founder, Chairman & CEO, METiS TechBio
Shuangjia Zheng:Researcher, Lingang Laboratory; Associate Professor, Shanghai Jiao Tong University